pulseline logo

A Pandora’s Box of Possibilities for World First Trial

[vc_row][vc_column][vc_column_text]The Royal Melbourne Hospital will begin an early feasibility study for the safety of the Stentrode™ device. The Stentrode™ is a device that is placed inside a blood vessel of the brain located in the area that controls movement, the motor cortex.

Once implanted, the Stentrode™ picks up signals and transmits them to artificial intelligence software that can allow a person to communicate or control a computer.

It is the only investigational technology of its kind that does not require open brain surgery.

Five participants with loss of motor function due to paralysis from spinal cord injury, motor neuron disease, stroke, muscular dystrophy and loss of limbs were chon to take place in the ground-breaking trial. The research will be the first of its kind to be performed in humans and will attempt to find safer, more effective ways to implant electrical sensors in patients’ brains.

Testing is supported by Synchron (formerly known as SmartStent) that spun out of the University of Melbourne. A company that was founded in 2012 after a cold-call pitch to the Pentagon with a new concept for a Brain-Computer Interface by CEO and founder Thomas Oxley.

Synchron claims this technology has the potential to enable patients with paralysis to take back digital control of their world, without having to move a muscle.[/vc_column_text][/vc_column][/vc_row]

Related Stories

Featured, Future of MedTech

You have subscribed